A detailed history of Quest Partners LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Quest Partners LLC holds 2,512 shares of DNLI stock, worth $63,201. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,512
Holding current value
$63,201
% of portfolio
0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$20.96 - $31.05 $52,651 - $77,997
2,512 New
2,512 $73.2 Million
Q4 2023

Feb 09, 2024

BUY
$16.2 - $23.18 $161,433 - $230,988
9,965 New
9,965 $214 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.38B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.